EGFR and non-small cell lung carcinoma: Osimertinib is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have an EGFR exon 19 deletion or L858R mutation, or for those patients with T790M mutation-positive metastatic NSCLC who had progressed during or after first- or second-generation EGFR TKI therapy (60).